Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (231-240 of 627) with videos related to

Pageof 63
Sort By:
The American Journal of Cardiology|August 30, 2008
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)James M Yau, John H Alexander, Gail Hafley, et al.
Journal of Thrombosis and Thrombolysis|May 10, 2006
Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiativeKanwar P Singh, Matthew T Roe, Eric D Peterson, et al.
Contemporary Clinical Trials|July 23, 2008
Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX libraryKenneth W Mahaffey, Craig J Reist, Yuling Fu, et al.
American Heart Journal|August 1, 2006
Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overviewKenneth W Mahaffey, Frans Van de Werf, Stanton K Shernan, et al.
American Heart Journal|June 2, 2015
The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborationsMatthew T Roe, Kenneth W Mahaffey, Justin A Ezekowitz, et al.
Circulation|June 27, 2018
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney FunctionBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
American Heart Journal|September 1, 1999
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary ArteriesK W Mahaffey, C B Granger, M A Sloan, et al.
European Heart Journal|February 10, 2000
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUITK M Akkerhuis, J W Deckers, E Boersma, et al.
The Lancet. Diabetes & Endocrinology|September 10, 2019
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysisBrendon L Neuen, Tamara Young, Hiddo J L Heerspink, et al.
European Journal of Heart Failure|June 27, 2024
Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trialMuthiah Vaduganathan, Christopher P Cannon, Meg J Jardine, et al.
Pageof 63

Showing results (231-240 of 627) with videos related to

Sort By:
Pageof 63
The American Journal of Cardiology|August 30, 2008
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)James M Yau, John H Alexander, Gail Hafley, et al.
Journal of Thrombosis and Thrombolysis|May 10, 2006
Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiativeKanwar P Singh, Matthew T Roe, Eric D Peterson, et al.
Contemporary Clinical Trials|July 23, 2008
Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX libraryKenneth W Mahaffey, Craig J Reist, Yuling Fu, et al.
American Heart Journal|August 1, 2006
Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overviewKenneth W Mahaffey, Frans Van de Werf, Stanton K Shernan, et al.
American Heart Journal|June 2, 2015
The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborationsMatthew T Roe, Kenneth W Mahaffey, Justin A Ezekowitz, et al.
Circulation|June 27, 2018
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney FunctionBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
American Heart Journal|September 1, 1999
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary ArteriesK W Mahaffey, C B Granger, M A Sloan, et al.
European Heart Journal|February 10, 2000
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUITK M Akkerhuis, J W Deckers, E Boersma, et al.
The Lancet. Diabetes & Endocrinology|September 10, 2019
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysisBrendon L Neuen, Tamara Young, Hiddo J L Heerspink, et al.
European Journal of Heart Failure|June 27, 2024
Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trialMuthiah Vaduganathan, Christopher P Cannon, Meg J Jardine, et al.
Pageof 63